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Sir,
Candida species is the fourth leading cause of nosocomial blood-
stream infection in the USA. The incidence and mortality of invasive
candidiasis (IC) remain high despite new antifungal agents.
Although Candida albicans remains the most common isolated
species causing IC, the incidence of IC caused by non-albicans
species is increasing.1 Caspofungin, an echinocandin, is approved for
treatment of IC.2 Resistance to caspofungin has been rarely reported.
We admitted a 28-year-old female with acute myelogenous leu-
kaemia (AML) for fever and otitis media. She was started on cas-
pofungin [70 mg intravenous (iv) loading dose followed by 50 mg
iv daily] on her fifth hospital day due to persistent fever despite iv
broad-spectrum antibiotics. Defervescence was noted and she was
started on induction chemotherapy for AML on the sixth hospital
day. She again developed fever with symptoms of oesophagitis
on her 21st hospital day. Oesophagogastroduodenoscopy
with oesophageal biopsy was performed and showed invasive
candidal oesophagitis. Caspofungin was switched to liposomal
amphotericin B. Her repeat blood cultures grew Candida
tropicalis susceptible to fluconazole. Amphotericin B was
switched to fluconazole and the patient improved slowly. She
completed 4 weeks of fluconazole treatment.
We subsequently performed additional in vitro MIC testing
for echinocandins on the isolated C. tropicalis using the CLSI
(formerly NCCLS) M27-A2 standard methods.3 This method
has been proven to be reproducible and reliable in the study of
MIC trends and patterns of antifungal medications.4 MICs of
caspofungin, micafungin and anidulafungin were 4.0, 8.0 and
1.0 mg/L, respectively.
This is the first documented case of C. tropicalis infection
clinically resistant to caspofungin. This suggests that all Candida
species are capable of developing resistance to echinocandins.
The CLSI has established an echinocandin MIC of .2 mg/L to
identify ‘non-susceptible’ Candida species.5 Our isolated strain’s
caspofungin MIC is consistent with this breakpoint.
We also observed cross-resistance of the isolated species to
micafungin. This pattern of cross-resistance is similar to the obser-
vations made by Mougdal et al.6 for Candida parapsilosis. This
may suggest a similar mechanism of resistance of Candida species
to echinocandins, specifically caspofungin and micafungin.
Four mechanisms of reduced susceptibility to caspofungin
have been suggested: (i) fks1 gene mutation; (ii) efflux-based
mechanism; (iii) Sbe2p overexpression; and (iv) paradoxical or
eagle effect.1,7 Only the fks1 gene mutation, however, is proven
to cause clinical failure with caspofungin therapy.1 Further
investigation of the fks1 gene of our isolated strain would help
support Candida species’ similarity of mechanism for echino-
candin resistance.
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Sir,
Pseudomonas aeruginosa is one of the most frequently isolated
Gram-negative pathogens associated with hospital-acquired
infections. The carbapenems, imipenem and meropenem, have a
broad spectrum of activity and are considered the agents of
choice for the treatment of P. aeruginosa infections. However,
metallo-b-lactamases (MBLs), which readily hydrolyse most
b-lactams, including carbapenems, are increasingly being ident-
ified among P. aeruginosa clinical isolates. The VIM-type
MBLs have been widespread in Asia, Southern Europe and
North America.1 Since 2000, the Antibiotic Resistance
Monitoring and Reference Laboratory has received approxi-
mately 80 isolates, mostly Pseudomonas species, from the UK,
which tested positive for blaVIM (Dr Neil Woodford, Health
Protection Agency, London, personal communication). This
study describes the first identification of blaVIM-2 in Ireland.
P. aeruginosa isolates 32297 and 15488 were isolated from a
swab and a sputum sample, respectively, from the same patient
at St James’s Hospital, Dublin, Ireland. These isolates were
74.3% similar with more than three band differences, as deter-
mined by XbaI restriction digest and separation using PFGE, and
thus considered unrelated. Both isolates were resistant to imipe-
nem and meropenem using the CLSI guidelines.2 Isolate 32297
had imipenem and meropenem MICs of 64 and 16 mg/L,
respectively. Isolate 15488 had imipenem and meropenem MICs
of .128 mg/L for both carbapenems. Both isolates had a
reduction in imipenem and meropenem MICs of greater than 3
doubling dilutions in the presence of EDTA (320 mg/L),
suggesting the presence of an MBL. This was confirmed by the
MBL Etest (AB Biodisk, Solna, Sweden). blaVIM- and
blaIMP-positive controls were included in each test. Isoelectric
focusing was performed using the methods of Matthew et al.3
blaVIM- and blaIMP-positive controls were included in the gels.
The blaVIM control had pI values of 8.65, 6.85 and 6.75. Isolate
15488 had pI values of 8.65, 7.2 and 6.65 and isolate 33075 had
values of 8.15 and 7.85. Both isolates were screened by PCR for
the presence of blaVIM, blaIMP, blaSPM and blaGIM genes. Isolate
15488 was blaVIM-positive by PCR. The blaVIM gene was ampli-
fied by PCR and sequenced using primers forward 50-GGC ATC
CAA GCA GCA AG-30 and reverse 50-AAG CAG ACT TGA
CCT GA-30 for the amplification of the entire gene, which yield
an 800 bp PCR product. The PCR product of 15488 had 100%
identity with the blaVIM-2 gene, GenBank accession number
AY943084.1. Sequencing results also revealed that the blaVIM-2
gene of 15488 was inserted as a single gene cassette into a class
1 integron. The two isolates were tested phenotypically for the
presence of efflux pumps by measuring the meropenem MIC in
the presence of efflux pump inhibitors carbonyl cyanide
m-chlorophenylhydrazone (50 mg/L) and phenyl-arginine-
b-naphthylamide (20 mg/L).4,5 There were no changes in the
carbapenem MICs in the presence of the efflux pump inhibitors.
The outer membrane proteins of the two clinical isolates, the
blaVIM and blaIMP controls and the susceptible strain ATCC
27853 were extracted from exponentially growing cells. Both
clinical isolates, in contrast to the susceptible ATCC 27853
strain, had loss of a 46 kDa protein band, which corresponds to
the OprD porin. Isolate 33075 was PCR-negative for the tested
MBLs, although a reduction in carbapenem MIC in the presence
of EDTA has been detected. Such false-positive results could
be attributed to the EDTA interference with the cell wall per-
meability as EDTA affects the regulation of the OprD porin and
may facilitate the entry of carbapenems.6
To the best of our knowledge, this is the first report of an
MBL-producing P. aeruginosa isolate from Ireland. The MBL
was not associated with an outbreak. The integron did not
contain other resistance gene determinants. Although this isolate
was not associated with an outbreak, the identification of this
carbapenemase on a mobile element poses a threat to infection
control. Carbapenem-resistant blaVIM-2-producing P. aeruginosa
clones have emerged in several countries such as Portugal,
Poland, Spain, Italy, Greece and Japan and can be attributed to
the spread of blaVIM-2-producing P. aeruginosa. Therefore, con-
tinued monitoring and surveillance of P. aeruginosa for MBLs
is required to minimize the threat of outbreaks. The identifi-
cation of blaVIM-2 in Ireland also indicates that MBLs from their
original reports in southern Europe have been further spread
within Europe.
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